1-(4-(hexyloxy)phenyl)-3-(piperidin-1-yl)propan-1-one | 82935-09-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-(hexyloxy)phenyl)-3-(piperidin-1-yl)propan-1-one
• 英文别名: 3-Piperidino-1-(4-hexyloxyphenyl)-propan-1-on；4'-hexyloxy-3-piperidinopropiophenone；1-(4-Hexyloxy-phenyl)-3-piperidin-1-yl-propan-1-one；1-(4-hexoxyphenyl)-3-piperidin-1-ylpropan-1-one
• CAS: 82935-09-9
• 化学式: C₂₀H₃₁NO₂
• 分子量: 317.472
• InChiKey: WXYWMSOSIIBMMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  23
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  哌啶 、 1-<(4-hexyloxy)phenyl>-3-chloropropan-1-one 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 为溶剂， 以83%的产率得到1-(4-(hexyloxy)phenyl)-3-(piperidin-1-yl)propan-1-one
  参考文献：
  名称：

  Improvement of Pharmacological Properties of Irreversible Thyroid Receptor Coactivator Binding Inhibitors

  摘要：

  We have previously reported the discover), and preliminary structure activity relationships of a series of beta-aminoketones that disrupt the binding of coactivators to TR. However, the most active compounds had moderate inhibitory potency and relatively high cytotoxicity, resulting in narrow therapeutic index. Additionally, preliminary evaluation of in vivo toxicology revealed a significant dose related cardiotoxicity. Here we describe the improvement of pharmacological properties of thyroid hormone receptor coactivator binding inhibitors. A comprehensive Survey of the effects of substitutents in key areas of the molecule was carried out based on mechanistic insight from the earlier report. This study revealed that both electron withdrawing and hydrophobic substituents on the aromatic ring led to higher potency. On the other hand, moving from an alkyl to a sulfonyl alkyl side chain led to reduced cytotoxicity, Finally, utilization of airline moieties having low pK(a)'s resulted in lowered ion channel activity without any loss of pharmacological activity.

  DOI：

  10.1021/jm9002704

文献信息

• [EN] 1-PHENYLPROPANONE COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS DE 1-PHÉNYLPROPANONE ET LEUR UTILISATION
  申请人：UNIV DEGLI STUDI PADOVA

  公开号：WO2018060947A1

  公开（公告）日：2018-04-05

  The present invention relates to a 1-phenylpropanone compound of formula (I), wherein X is CH2 or an atom selected from the group consisting of O, S and Se, n is an integer from 4 to 6, A is a substituent selected from the group consisting of 4-morpholyl, 1-piperidinyl, 4-methyl-1-piperazinyl, A being optionally substituted with a (C1-C3)alkyl or (C1-C3)acyl substituent, with the proviso that when X is CH2, n is equal to 5, for use as an antitumoral agent in the treatment of breast cancer, chronic lymphatic leukemia or neuroblastoma. The invention also concerns new 1-phenylpropanone compounds, and compounds as antitumoral agents.

  本发明涉及一种化合物，其化学式为(I)，其中X为CH2或从O、S和Se组成的原子中选择的一个，n为4到6之间的整数，A为从4-吗啡基、1-哌啶基、4-甲基-1-哌嗪基中选择的取代基，A可以选择地与(C1-C3)烷基或(C1-C3)酰基取代，但当X为CH2时，n等于5，用作抗肿瘤剂治疗乳腺癌、慢性淋巴细胞白血病或神经母细胞瘤。该发明还涉及新的1-苯基丙酮化合物，以及作为抗肿瘤剂的化合物。
• Anaesthetic lozenges and method of preparing them
  申请人：BEECHAM INC.

  公开号：EP0001907A1

  公开（公告）日：1979-05-16

  Anesthetic lozenges are prepared by combining an acid addition salt of 3-piperidino ρ- alkoxypropionphenones with a molten hard candy base with either the prior or simultaneous addition of a stabilizing amount of a pharmaceutically acceptable acid such as citric acid.

  将 3-哌啶基ρ-烷氧基丙酮的酸加成盐与熔融硬糖基料结合，并事先或同时加入一定量的药学上可接受的稳定酸（如柠檬酸），即可制备出麻醉锭剂。
• Anesthetic oral compositions
  申请人：Richardson-Vicks, Inc.

  公开号：EP0383481A2

  公开（公告）日：1990-08-22

  Disclosed are oral anesthetic pharmaceutical compositions compris­ing: (a) from about 0.02% to about 25% of a pharmaceutically accept­able acid salt of a β-aminopropiophenone, such as dyclonine HCl; (b) from about 0.02% to about 20% of saccharin; and (c) from about 1% to about 99% of a pharmaceutically acceptable oral carrier. Also provided are methods for providing an anesthetic effect in humans or animals which comprises orally administering to said human or animal a safe and effective amount of these pharmaceutical compositions. Also provided is a novel process for the manufacture of anesthetic lozenges contain­ing a β-aminopropiophenone along with saccharin.

  所公开的口服麻醉药物组合物包含：(a) 约 0.02% 至约 25% 的药学上可接受的 β-氨基苯丙酮酸盐，如盐酸地氯诺宁；(b) 约 0.02% 至约 20% 的糖精；以及 (c) 约 1% 至约 99% 的药学上可接受的口服载体。还提供了为人类或动物提供麻醉效果的方法，其中包括向所述人类或动物口服安全有效量的这些药物组合物。还提供了一种制造含有β-氨基苯丙酮和糖精的麻醉锭剂的新工艺。
• 1-PHENYLPROPANONE COMPOUNDS AND USE THEREOF
  申请人：Universita' Degli Studi Di Padova

  公开号：EP3518927B1

  公开（公告）日：2020-08-12
• US4139627A
  申请人：——

  公开号：US4139627A

  公开（公告）日：1979-02-13